Finally, the impact of patient heterogeneity—including age, sex, obesity, and genetic background—on SGLT2 expression and therapeutic responsiveness has not been systematically examined but is likely to be critical to the development of precision medicine approaches. This evidence concerns the gene SLC5A2 and Obesity.